NEJM study found Zetia uptake rose quicker in US vs. Canada

Share this article:
A New England Journal of Medicine study found Zetia uptake rose much more quickly after introduction in the US than in Canada, and suggested DTC was the main culprit. “Despite the absence of data regarding clinical outcomes, ezetimibe was heavily promoted,” the study's authors wrote, citing Nielsen numbers showing that more than $200 million was spent advertising Vytorin to US consumers in 2007, while consumer ads are prohibited in Canada.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.